These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 7156000)

  • 1. Oral immunization against influenza.
    Waldman RH; Lazell VA; Bergmann KC; Khakoo R; Jacknowitz AI; Howard SA; Rose C
    Poumon Coeur; 1982; 38(5):293-6. PubMed ID: 7156000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization against influenza in humans using an oral enteric-coated killed virus vaccine.
    Lazzell V; Waldman RH; Rose C; Khakoo R; Jacknowitz A; Howard S
    J Biol Stand; 1984 Jul; 12(3):315-21. PubMed ID: 6480615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine.
    Bergmann KC; Waldman RH; Tischner H; Pohl WD
    Int Arch Allergy Appl Immunol; 1986; 80(1):107-9. PubMed ID: 3957442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.
    Avtushenko SS; Sorokin EM; Zoschenkova NY; Zacharova NG; Naichin AN
    J Biotechnol; 1996 Jan; 44(1-3):21-8. PubMed ID: 8717382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory immune response after nasal vaccination with live attenuated influenza viruses.
    Crifö S; Vella S; Filiaci F; Resta S; Rocchi G
    Rhinology; 1980 Jun; 18(2):87-92. PubMed ID: 7403787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization against influenza in children with asthma and chronic bronchitis.
    Bergmann KC; Waldman RH; Reinhöfer M; Pohl WD; Tischner H; Werchan D
    Adv Exp Med Biol; 1987; 216B():1685-90. PubMed ID: 3425455
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretory antibody following oral influenza immunization.
    Waldman RH; Stone J; Bergmann KC; Khakoo R; Lazzell V; Jacknowitz A; Waldman ER; Howard S
    Am J Med Sci; 1986 Dec; 292(6):367-71. PubMed ID: 3541604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Secretory immunity of the nasal mucosa and its relevance to influenza].
    Meyer P; Werner E
    Z Arztl Fortbild (Jena); 1985; 79(5):195-7. PubMed ID: 2408391
    [No Abstract]   [Full Text] [Related]  

  • 13. [The development of mucosal vaccines].
    Bakke H; Haneberg B
    Tidsskr Nor Laegeforen; 2006 Nov; 126(21):2818-21. PubMed ID: 17086224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa.
    Brokstad KA; Eriksson JC; Cox RJ; Tynning T; Olofsson J; Jonsson R; Davidsson A
    J Infect Dis; 2002 Apr; 185(7):878-84. PubMed ID: 11920311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
    Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
    Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response in respiratory secretions of volunteers given live and dead influenza virus.
    Mann JJ; Waldman RH; Togo Y; Heiner GG; Dawkins AT; Kasel JA
    J Immunol; 1968 Apr; 100(4):726-35. PubMed ID: 5645216
    [No Abstract]   [Full Text] [Related]  

  • 19. Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens.
    Chiou CJ; Tseng LP; Deng MC; Jiang PR; Tasi SL; Chung TW; Huang YY; Liu DZ
    Biomaterials; 2009 Oct; 30(29):5862-8. PubMed ID: 19608270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
    Pialoux G; Hocini H; Pérusat S; Silberman B; Salmon-Ceron D; Slama L; Journot V; Mathieu E; Gaillard C; Petitprez K; Launay O; Chêne G;
    Vaccine; 2008 May; 26(21):2657-66. PubMed ID: 18068876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.